[A case of delayed colonic perforation after metallic stent placement for advanced descending colon cancer during bevacizumab-based chemotherapy].
A 73-year-old man with advanced descending colon cancer and peritoneal metastases underwent a self-expandable metallic stent placement under fluoroscopic guidance on October 2007. The stent placement was successful without early complication. After 6 courses of FOLFOX4 followed by 7 courses of FOLFIRI, he received Bevacizumab-based chemotherapy from August 2008. In April 2009, he was admitted to our hospital with severe abdominal pain due to perforation of descending colon. Although emergent surgery was performed, he developed DIC and died on the 21 postoperative days. This case suggests that metallic stent placement for colorectal cancer cases might increase the risk of bowel perforation during Bevacizumab-based chemotherapy.
Dept. of Gastroenterology, Date Red Cross General Hospital.
Ikuta
I
Tanaka
Hiroyuki
H
Hisai
Etsu
E
Miyazaki
Michihiro
M
Ono
Yoshiharu
Y
Maeda
Masafumi
M
Sato
Ryosuke
R
Kawasaki
Hiroshi
H
Gyobu
Seiichiro
S
Nakajima
Syota
S
Yamada
Hiroshi
H
Muramatsu
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017809:Fatal Outcome; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000601:surgery; D008297:Male; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D015607:Stents
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab